| 18.415 0.025 (0.14%) | 09-23 10:43 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 27.54 | 1-year : | 32.07 |
| Resists | First : | 23.58 | Second : | 27.45 |
| Pivot price | 18.67 |
|||
| Supports | First : | 17.3 | Second : | 14.4 |
| MAs | MA(5) : | 18.07 |
MA(20) : | 20 |
| MA(100) : | 23.87 |
MA(250) : | 25.38 |
|
| MACD | MACD : | -1.9  |
Signal : | -1.9 |
| %K %D | K(14,3) : | 15.2 |
D(3) : | 11.5 |
| RSI | RSI(14): 35.1 |
|||
| 52-week | High : | 34.27 | Low : | 17.3 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ENOV ] has closed above bottom band by 30.3%. Bollinger Bands are 54.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 18.65 - 18.74 | 18.74 - 18.82 |
| Low: | 17.91 - 18.01 | 18.01 - 18.1 |
| Close: | 18.23 - 18.4 | 18.4 - 18.53 |
Enovis Corporation is a global medical technology enterprise specializing in the design, production, and supply of medical devices. These specialized products are instrumental for a diverse range of healthcare professionals—including orthopedic specialists, surgeons, general physicians, pain management experts, physical therapists, podiatrists, chiropractors, and athletic trainers—who treat patients with musculoskeletal conditions resulting from degenerative illnesses, deformities, traumatic events, or sports-related injuries. The company's extensive product line encompasses rigid and flexible orthopedic supports, thermal and cryotherapy items, bone growth stimulation devices, vascular therapy systems paired with compression garments, therapeutic footwear and orthotics, electrical stimulators for pain alleviation, and physical rehabilitation equipment. Additionally, Enovis provides a comprehensive array of reconstructive joint implants for areas such as the hip, knee, shoulder, elbow, foot, ankle, and fingers. Enovis Corporation distributes its products through a network of independent channels, including healthcare providers, retail establishments, and pharmacies, in addition to direct sales under its prominent DJO brand. Previously known as Colfax Corporation, the company is headquartered in Wilmington, Delaware.
Tue, 22 Sep 2026
Enovis becomes first multi-registry industry sponsor of AAOS Registry Program - Stock Titan
Thu, 17 Sep 2026
Enovis Corp (ENOV) Shares Fall 4.6% -- What GF Score of 61 Tells Investors - gurufocus.com
Tue, 08 Sep 2026
Enovis CORP (ENOV) insider adds 2,660 shares in open-market buy - Stock Titan
Fri, 04 Sep 2026
Enovis (NYSE: ENOV) executive buys 7,598 shares outside 10b5-1 plan - Stock Titan
Thu, 03 Sep 2026
What Makes Enovis (ENOV) a New Buy Stock - Yahoo Finance
Tue, 01 Sep 2026
Enovis drops 17% on binding offer to acquire eCential Robotics (ENOV:NYSE) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 58 (M) |
| Shares Float | 53 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 125 (%) |
| Shares Short | 8,710 (K) |
| Shares Short P.Month | 8,340 (K) |
| EPS | -19.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 25.61 |
| Profit Margin | -48 % |
| Operating Margin | 4.1 % |
| Return on Assets (ttm) | 1.1 % |
| Return on Equity (ttm) | -54.2 % |
| Qtrly Rev. Growth | 3.2 % |
| Gross Profit (p.s.) | 24.44 |
| Sales Per Share | 39.88 |
| EBITDA (p.s.) | 6.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 270 (M) |
| Levered Free Cash Flow | 186 (M) |
| PE Ratio | -0.94 |
| PEG Ratio | 3.4 |
| Price to Book value | 0.7 |
| Price to Sales | 0.45 |
| Price to Cash Flow | 3.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|